NCT04508426 is a Phase 1 clinical trial of [14C]AR882 in Healthy Volunteers, sponsored by Arthrosi Therapeutics.

Who is sponsoring NCT04508426?

NCT04508426 is sponsored by Arthrosi Therapeutics.

What drugs are being tested in NCT04508426?

Interventions in NCT04508426: [14C]AR882.

What condition does NCT04508426 study?

NCT04508426 studies Healthy Volunteers.

Is NCT04508426 still recruiting?

NCT04508426 is currently completed. Last updated 16 November 2020.

Last reviewed 2020-11-16 · How we verify

NCT04508426

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

Completed Phase 1 Last updated 16 November 2020

What this trial tests

Phase 1 trial testing [14C]AR882 in Healthy Volunteers in 6 participants. Completed in 12 August 2020.

Timeline

16 July 2020

Primary endpoint
12 August 2020

12 August 2020

Quick facts

Lead sponsor	Arthrosi Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	16 July 2020
Primary completion	12 August 2020
Estimated completion	12 August 2020
Sites	1 location across United States

Drugs / interventions tested

[14C]AR882 — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Arthrosi Therapeutics — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single dose of \[14C\]AR882 in healthy adult male subjects. Whole blood, plasma, urine, and fecal samples will be analyzed for at least 144 hours following the single dose of AR882 to measure total radioactivity and plasma drug concentrations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Review of Urate-Lowering Therapeutics: From the Past to the Future.
Jenkins C, Hwang JH, Kopp JB, Winkler CA, et al · · 2022 · cited 38× · PMID 36081938 · DOI 10.3389/fphar.2022.925219

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Arthrosi Therapeutics trials

Trials by the same sponsor.

NCT05253833 — Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout · Phase 2 · completed
NCT05119686 — Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients · Phase 2 · completed
NCT04646889 — Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment · Phase 1 · completed
NCT04155918 — Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients · Phase 2 · completed
NCT04314986 — Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04508426 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arthrosi Therapeutics
Last refreshed: 16 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04508426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing